Published in final edited form as:

Horm Cancer. 2014 October ; 5(5): 284–298. doi:10.1007/s12672-014-0192-z.

Progesterone and estradiol synergistically promote the lung metastasis of tuberin-deficient cells in a preclinical model of lymphangioleiomyomatosis

Yang Sun¹, Erik Zhang¹, Taotao Lao², Ana M. Pereira¹, Chenggang Li¹, Li Xiong¹, Tasha Morrison¹, Kathleen J. Haley¹, Xiaobo Zhou², and Jane J. Yu¹

¹Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, One Blackfan Circle, 6th Floor, Boston, MA 02115

²Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, 181 Longwood Avenue, Boston, MA 02115

Abstract

Lymphangioleiomyomatosis (LAM) is a female-predominant lung disease that can lead to respiratory failure. LAM cells typically have inactivating *TSC2* mutations, leading to mTORC1 hyperactivation. The gender specificity of LAM suggests that female hormones contribute to disease progression. Clinical findings indicate that estradiol exacerbates LAM behaviors and symptoms. Although hormonal therapy with progesterone has been employed, the benefit in LAM improvement has not been achieved. We have previously found that estradiol promotes the survival and lung metastasis of cells lacking tuberin in a preclinical model of LAM. In this study, we hypothesize that progesterone alone or in combination with estradiol promote metastatic behaviors of *TSC2*-deficient cells. In cell culture models of *TSC2*-deficient LAM patient-derived and rat uterine leiomyoma-derived cells, we found that progesterone treatment or progesterone plus estradiol resulted in increased phosphorylation of Akt and ERK1/2, induced the proliferation, and enhanced the migration and invasiveness. In addition, treatment of progesterone plus estradiol synergistically decreased the levels of reactive oxygen species, and enhanced cell survival under oxidative stress. In a murine model of LAM, treatment of progesterone plus estradiol promoted the growth of xenograft tumors; however, progesterone treatment did not affect the development of xenograft tumors of *Tsc2*-deficient cells. Importantly, treatment of progesterone plus estradiol resulted in alteration of lung morphology, and significantly increased the number of lung micrometastases of *Tsc2*-deficient cells compared with estradiol treatment alone. Collectively, these data indicate that progesterone increases the metastatic potential of *TSC2*-deficient LAM patient-derived cells in vitro and lung metastasis in vivo. Thus, targeting progesterone-mediated signaling events may have therapeutic benefit for LAM and possibly other hormonally dependent cancers.

Corresponding author: Jane J. Yu, Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston MA 02115, Tel: 617 355 9049 jyu13@rics.bwh.harvard.edu.

Conflict of interest. The authors declare that there are no conflicts of interest.

Keywords

tuberin; Akt; ERK1/2; lung metastasis; alveolar integrity; migration; invasiveness; oxidative stress; progesterone; estradiol; tuberin

Introduction

LAM is a progressive lung disease that affects almost exclusively women. The pathogenesis of the sporadic form of LAM is unusual: LAM cells are histological benign smooth muscle cells that metastasize to the lungs [1], where they cause emphysema-like cystic lung degeneration in young, otherwise healthy, non-smoking women [2, 3]. The majority of LAM patients also have renal angiomyolipomas, which are benign tumors containing smooth muscle cells that are indistinguishable from LAM cells. LAM and angiomyolipoma cells have mutations in *TSC1* or *TSC2*, leading to activation of the mammalian target of rapamycin complex 1 (mTORC1). mTORC1 regulates cell growth, protein translation, and metabolism. Treatment with Rapamycin, an mTORC1 inhibitor, can stabilize lung function in LAM but lung function decline continues when the drug is discontinued [4]. The only proven treatment for end-stage disease is lung transplantation, after which LAM can recur in the transplanted lungs [5].

The female predominance of LAM, coupled with the genetic data indicating that estradiol may promote LAM pathogenesis. Both LAM cells and renal angiomyolipoma cells express estradiol receptor alpha and progesterone receptor [6–13]. LAM occurs exclusively in women during their reproductive age, and the symptoms of LAM become complicated during pregnancy [3, 14, 15], and by administration of exogenous estradiol [16–18]. These clinical findings provided rationales for hormonal therapy, particularly using progesterone, for the treatment of women with LAM; however, the benefit has not been successfully demonstrated [19–21].

In preclinical models of LAM, estradiol promoted the survival and metastasis of TSC2-deficient cells [22–24]. Faslodex, a pure estradiol receptor antagonist, blocked estradiol-induced lung metastasis of Tsc2-deficient cells in a metastatic model [25]. In addition, it has been shown that estradiol promoted whereas tamoxifen suppressed the development of liver hemangiomas in *Tsc1* heterozygous mice [26]. Furthermore, in a recently developed uterine-specific *Tsc2* knockout mouse model, estradiol treatment increased myometrial proliferation, which was suppressed by ovariectomy and aromatase inhibition. Interestingly, progesterone treatment did not affect the proliferation of myometrial [24]. Despite these findings, the impact of progesterone on the proliferation, survival, and metastasis of cells lacking TSC2 has not been extensively investigated.

We report here that progesterone treatment or progesterone plus estradiol activated Akt and ERK1/2 signaling pathways in LAM patient-derived cells. Importantly, progesterone alone or in combination with estradiol strongly enhanced the migration and invasiveness of TSC2-deficient cells. In addition, treatment of progesterone plus estradiol synergistically decreased the cellular levels of reactive oxygen species (ROS), and enhanced cell survival under oxidative stress. Furthermore, treatment of progesterone plus estradiol promoted the growth

of xenograft tumors; however, progesterone treatment did not affect the development of xenograft tumors of Tsc2-deficient cells. Importantly, treatment of progesterone plus estradiol promoted the lung metastasis of Tsc2-deficient cells compared with estradiol treatment alone. Collectively, these data demonstrate that progesterone, in addition to estradiol, increases the metastatic potential of TSC2-deficient LAM patient-derived cells in vitro and lung metastasis in vivo. Thus, targeting progesterone-mediated signaling and/or cellular events may have therapeutic benefit for LAM and possibly other hormonally dependent neoplasm.

Results

Progesterone activates ERK1/2 and Akt and enhances the proliferation of TSC2-deficient cells

LAM patient-associated angiomyolipoma-derived cells and rat uterine leiomyoma-derived cells express estrogen receptor alpha (ER α) and progesterone receptor (PgR), and respond to estradiol stimulation [27, 28]. The patient-derived cells were developed from a sporadic LAM-associated renal angiomyolipoma. These cells carry bi-allelic mutations of the TSC2 gene that are identical to the mutations found in the patient's pulmonary LAM cells [28]. The rat cells were developed from an Eker rat uterine leiomyoma, which is composed of smooth muscle cells lacking functional TSC2 [27, 29]. To validate the expression of ER α and PgR, we measured their transcript levels using quantitative RT-PCR. The relative transcript level of ER α was 4-fold higher in 621-101 cells (CT = 32.5) relative to normal human lung bronchial epithelial cells (BEAS-2B) (CT = 31.6) (Figure 1A). Interestingly, the transcript level of ER α was much lower in 621-101 cells relative to that in breast cancer MCF-7 cells (CT = 24.5) (Figure 1A). Moreover, the transcript level of PgR was detectable in 621-101 cells (CT = 31.6), although the value was lower than that of MCF-7 cells (CT = 22.2) (Figure 1A). Furthermore, the expression of ER α (CT = 34.5) and PgR (CT = 23.8) was confirmed in rat uterine leiomyoma-derived ELT3 cells (Figure 1A), consistent with previous findings [27, 28]. To further determine the accumulation of ER α and PgR in TSC2-deficient LAM patient-derived and rat-derived cells, we performed immunofluorescent staining of ER α and PgR in 621-101, ELT3-V3, BEAS-2B and MCF-7 cells. Nuclear staining of ER α and PgR was evident in both 621-101 and ELT3-V3 cells (Figure 1B). Intense nuclear staining of ER α and PgR was also found in MCF-7 cells as expected [30, 31]. Interestingly, nuclear staining of ER α and PgR was also observed in BEAS-2B, consistent with previous findings [32].

To determine the impact of progesterone stimulation on TSC2 deficient cells, we examined the activation of Akt and ERK1/2, which are known signaling molecules influenced by E₂ in TSC2-deficient cells [23, 25, 33–37]. We found that E₂ treatment for 0.5, 4 and 24 hr induced a biphasic activation of ERK1/2 (T202/Y204) by 70%, 20% and 140%, respectively, compared with vehicle control ($p < 0.01$, Figure 1C), as previously reported [23, 25, 33–37]. Interestingly, progesterone treatment for 0.5, 4 and 24 hr also induced a biphasic activation of ERK1/2 (T202/Y204) by 80%, 20% and 140%, respectively, compared with vehicle control, in TSC2-deficient LAM patient-derived cells ($p < 0.01$, Figure 1C). Moreover, progesterone treatment induced phosphorylation of Akt (Ser 473) at

0.5, 4 and 24 hr by 40%, 85% and 100% (Figure 1C). Importantly, the combination of progesterone and E₂ did not further increase the levels of phospho-Akt (Ser 473) or phospho-ERK1/2 (T202/Y204) compared with progesterone or E₂ treatment alone in LAM patient-derived cells (Figure 1C).

To determine the impact of progesterone stimulation on cell growth, we treated TSC2-deficient LAM patient-derived and rat-derived cells with progesterone, E₂, or progesterone plus E₂, for 24, 48, and 72 hr. Progesterone treatment did not affect the proliferation of LAM patient-derived cells (Figure 1D). Interestingly, progesterone plus E₂ enhanced the proliferation of LAM patient-derived cells ($p < 0.01$, Figure 1D). In rat-derived cells, progesterone alone had a modest effect in cell proliferation, but progesterone plus E₂ significantly increased cell proliferation ($p < 0.01$, Figure 1E). We also observed that E₂ promoted the growth of both LAM patient-derived and rat-derived cells, as previously reported [23, 33, 35, 36]. These data indicate that progesterone exerts differential actions on phosphorylation of signaling pathway components and the growth in TSC2-deficient cells in nutrient-poor conditions.

To determine whether patient-derived cells require steroids to grow in nutrient-rich conditions, we cultured these cells in complete media (containing steroids) or in phenol red-free media supplemented with charcoal-dextran stripped FBS (depleting steroids) for 72 hr, and measured cell growth at 24, 48 and 72 hr post cell seeding. We found that the growth rates of patient-derived cells were similar between steroids-containing and steroid-depleting conditions (Figure 1F), suggesting these patient-derived cells do not require steroids to grow in nutrient-rich conditions.

Progesterone enhances the migration of TSC2-deficient cells

We asked whether progesterone treatment affects the migration of TSC2-deficient. In rat-derived cells, progesterone increased the migration of cells by ~90% ($p < 0.01$, Figure 2A). E₂ stimulation also increased the number of migrating cells by ~110%. Interestingly, combination of progesterone and E₂ did not further enhance cell migration (Figure 2A). In LAM patient-derived cells, progesterone increased the migration of by ~80% ($p < 0.05$, Figure 2B). E₂ stimulation also increased the number of migrating cells by ~90%, confirming the finding by Gu et al [35]. Interestingly, combination of progesterone and E₂ did not further enhance cell migration compared to either steroid alone (Figure 2B).

To examine the effect of steroid hormone receptor antagonists in cell culture models, we tested the estrogen receptor antagonist ICI 182,780 (Fulvestrant) and PgR antagonist RU-486 (Mifepristone), singly or in combination, in TSC2-deficient patient-derived cells. First, ICI 182,780 or RU-486 single treatment suppressed E₂ or Pg-enhanced cell migration. The combination of ICI 182,780 and RU-486 also inhibited cell migration compared to either inhibitor alone (Figure 2B). These results point toward a critical role of progesterone/estradiol and PgR/ER α in the migration of TSC2-deficient cells.

Progesterone enhances the invasiveness of TSC2-deficient cells

We have previously reported that E₂ increased the invasion of rat-derived cells [25]. To examine whether progesterone treatment stimulates the invasiveness of TSC2-deficient, we

treated rat-derived and LAM patient-derived cells with progesterone, E₂, or progesterone plus E₂, for 24 hr, and then performed a Matrigel invasion assay. In rat-derived cells, progesterone increased the invasion of cells by 4-fold ($p < 0.05$, Figure 3A). E₂ stimulation also increased the number of invading cells by 4-fold, confirming the finding by Gu et al. [35]. Interestingly, combination of progesterone and E₂ did not further enhance cell invasion (Figure 3A). In patient-derived cells, progesterone increased the number of invading LAM patient-derived cells by ~3.5-fold ($p < 0.01$, Figure 3B). E₂ stimulation increased cell invasion by 4-fold, consistent with previous studies [25, 35]. Interestingly, the combination of progesterone and E₂ did not further increase cell invasion (Figure 3B). These results indicate that progesterone enhances the invasion of TSC2-deficient cells.

Next, we examined the consequence of ICI 182,780 and RU-486, singly or in combination, in the invasiveness of TSC2-deficient patient-derived cells. ICI 182,780 or RU-486 single treatment suppressed E₂ or Pg-enhanced cell invasion. The combination of ICI 182,780 and RU-486 also blocked cell invasion compared to vehicle control (Figure 3B). These results indicate a critical role of progesterone/estradiol and PgR/ER α in the invasion of TSC2-deficient cells.

Progesterone and estradiol synergistically decrease ROS in TSC2-deficient cells

We recently found that E₂ enhances the survival of TSC2-deficient cells [23], in part through the pentose phosphate pathway (PPP) [36]. We found that TSC2-deficient LAM patient-derived cells produced higher levels of ROS by 32% relative to TSC2-addback cells ($p < 0.01$, Figure 4A). Similarly, rat-derived cells produced higher levels of ROS levels by 28% relative to TSC2-addback cells ($p < 0.01$, Figure 4A), consistent with previous studies [33, 36].

We next measured the cellular levels of ROS in the presence or absence of hydrogen peroxide (H₂O₂). As expected, H₂O₂ treatment led to a 20% increase of ROS ($p < 0.01$, Figure 4B), and E₂ treatment decreased ROS levels by ~30% ($p < 0.01$, Figure 4B). Interestingly, progesterone treatment caused ~30% reduction of ROS levels relative to vehicle control ($p < 0.01$, Figure 4B). Importantly, progesterone plus E₂ decreased ROS levels, more so than either progesterone or E₂ in LAM patient-derived cells ($p < 0.01$, Figure 4B). Similar results on ROS production were also seen in Tsc2-deficient rat-derived cells (Figure 4C). These data indicate that progesterone and E₂ reduce the cellular levels of ROS. We then assessed the impact of progesterone and/or E₂ on the production of NADPH, a co-enzyme involved in protecting against the toxicity of ROS. E₂ increased the cellular levels of NADPH ($p < 0.05$, Figure 4D), as expected. However, progesterone or progesterone plus E₂ did not affect the levels of NADPH in LAM patient-derived cells (Figure 4D). These data indicate that progesterone and E₂ affect the oxidative stress response in cells lacking TSC2.

To define the mechanism responsible for the steroid-induced alteration of oxidative stress, we measured the intracellular levels of glutathione (GSH), an important antioxidant molecule protecting cells from damage caused by ROS. We found that E₂ plus Pg treatment resulted in 2.5-fold increase in intracellular GSH levels compared with the treatment of E₂ or Pg alone in patient-derived cells (Figure 4E), suggesting an important action of E₂ and Pg in oxidative defense in LAM patient-derived cells.

Progesterone and estradiol synergistically attenuate the death of TSC2-deficient cells

To assess the effect of progesterone and/or E₂ in the survival of TSC2-deficient cells under oxidative stress, cells were treated with H₂O₂ or vehicle control for 0.5 hr in the presence or absence of Pg, E₂, or Pg plus E₂ for additional 24 hr. Cell morphology showed that H₂O₂-triggered cell death was modestly rescued by Pg or E₂ treatment (Figure 5A), and strongly rescued by Pg plus E₂ stimulation in LAM patient-derived cells (Figure 5A) and rat-derived cells (Figure 5B). Using the PI exclusion assay, E₂ or Pg single treatment reduced cell death by 20% and 30% relative to vehicle control. The combination of progesterone and E₂ significantly reduced H₂O₂-induced cell death by 40% relative to control in rat-derived cells ($p < 0.01$, Figure 5C). In LAM patient-derived cells, E₂ or Pg single treatment reduced cell death by 10% and 10% relative to vehicle control. The combination of progesterone and E₂ significantly reduced H₂O₂-induced cell death by 30% relative to control LAM patient-derived cells ($p < 0.01$, Figure 5D). These data suggest that Pg and E₂ synergistically enhance the survival of TSC2-deficient cells particularly under conditions of oxidative stress.

Next, we examined the consequence of ICI 182,780 and RU-486, singly or in combination, in the survival of TSC2-deficient patient-derived cells. ICI 182,780 or RU-486 single treatment moderately increased E₂-reduced cell death by 5% and Pg-reduced cell death by 10%. The combination of ICI 182,780 and RU-486 more strongly increased cell death by 17% compared to either inhibitor alone (Figure 5F). These results indicate a critical role of progesterone/estradiol and PgR/ER α in the survival of TSC2-deficient cells under oxidative stress.

Progesterone and estradiol synergistically promote lung metastasis of Tsc2-deficient cells in a preclinical model of LAM

We previously found that E₂ promotes the lung metastasis of Tsc2-deficient ELT3 cells [23]. To determine whether progesterone singly or in combination with E₂ affects the metastasis of ELT3 cells, we supplemented female ovariectomized *scid* mice with slow-releasing pellets of progesterone, E₂, or the combination of progesterone and E₂, and then subcutaneously inoculated ELT3 cells. At week seven post cell inoculation, E₂ treatment increased the volume of xenograft tumors by 2.4-fold ($p < 0.01$, Figure 6A), consistent with our previous work [23]. Progesterone treatment did not affect the growth of xenograft tumors, and the combination of progesterone and E₂ increased the growth of xenograft tumors to the same extent as that of E₂ treatment (Figure 6A).

Lung metastases were scored by an observer blinded to the experimental conditions. Five of the ten E₂-treated mice (50%) developed lung metastases, with an average of four micrometastases/mouse (range 3–10) (Figure 6B). In contrast, only one of the ten placebo-treated mice (10%) developed a single metastasis, and none of mice treated with progesterone developed lung metastases. Importantly, lung metastases were identified in all four of the progesterone plus E₂ treated mice (100%) (Figure 6B), with an average of 12 micrometastases/mouse (range 5–20) (Figure 6B). Together, these data suggest that the combination of progesterone and E₂ more potently promote lung metastasis of Tsc2-deficient cells compared with E₂ treatment alone.

To qualify the *in vivo* findings that E₂ and Pg synergistically promote the lung metastasis of Tsc2-deficient cells, we first examined the lung morphology and identified the accumulation of abnormal cell clusters in the E₂ or E₂ plus Pg-treated mouse lungs compared with the vehicle treatment (Figure 6C). Interestingly, Pg treatment had no effect on lung metastasis of Tsc2-deficient ELT3 cells (Figure 6C). Next, we performed immunostaining of lung lesions for smooth muscle actin (SMA), phospho-S6 (S235/236) and PCNA. We found that E₂- and E₂ plus Pg-promoted lung metastatic lesions cells are positive for smooth muscle actin (Figure 6D), confirming the leiomyoma origin [23, 27, 29]; positive for phospho-S6 (Figure 6D), indicating the mTORC1 hyperactivation [38]; and positive for PCNA, suggesting the proliferating tumor cells in the lung (Figure 6E).

Progesterone induces alveolar wall thickening in a preclinical model of LAM

Despite the fact that progesterone did not affect lung metastasis of Tsc2-deficient cells (Figure 6), the evaluation of lung morphology from hematoxylin and eosin stained section showed striking interstitial alterations in Pg-treated mouse lungs compared with all other treatment groups (Figure 7A). To define the lung interstitial alterations, we first quantified the area of the alveolar space and found that Pg treatment markedly reduces the alveolar area relative to all other treatment groups (Figure 7B), indicating the development of alveolar thickening. Next, we tested the hypothesis of immune cell infiltration by immunostaining for lymphocyte common antigen (LCA, or CD45). We observed abundant accumulation of LCA-positive cells in the alveolar wall of lungs from a Pg-treated mouse (Figure 7C), suggesting that Pg-induced lung alteration is associated with lymphocyte infiltration. We also hypothesized that progesterone treatment causes thickening of alveolar epithelium. We performed immunofluorescent staining of lung sections with surfactant protein C (SPC), a marker for alveolar epithelial type II cells. Surprisingly, we found that Pg-treatment increased the accumulation of SPC-positive cells in alveolar space compared with all other treatments (Figure 7D), suggesting a specific role of progesterone in regulating alveolar wall integrity.

Discussion

LAM is a female predominant lung disease characterized by the abnormal proliferation of smooth muscle cells and progressive cystic destruction that can lead to respiratory failure and fatality [3, 15]. The gender specificity of LAM suggests that circulating female hormones including progesterone and estradiol may contribute to disease development. However, the mechanisms responsible for the action of progesterone and estradiol in cells with TSC2 deficiency have not been extensively studied. In current study we found that progesterone or progesterone plus estradiol activated Akt and ERK1/2, stimulated the proliferation, and promoted the migration and invasiveness of TSC2-deficient LAM patient-derived and rat-uterine leiomyoma-derived ELT3 cells *in vitro*. Moreover, progesterone plus estradiol synergistically reduced the cellular levels of ROS, increased the levels of glutathione, and enhanced cell survival under oxidative stress. *In vivo*, combination of progesterone and estradiol promoted the growth of xenograft tumors of Tsc2-deficient cells. Importantly, treatment of progesterone plus estradiol increased the number of lung

micrometastases of Tsc2-deficient cells compared with estradiol treatment. Interestingly, progesterone induced immune cell infiltration and alveolar wall thickening.

In the past 35 years, anti-estrogen therapies have been used in the treatment of LAM; however, the benefit of progesterone therapy has not been promising in most of the clinical studies [20, 21, 39–46]. Our in vitro and in vivo results differ from previous studies. We hypothesize that E₂ drives and Pg enhances the metastatic potential of Tsc2-deficient cells via the cognate receptors ER α and PgR. Importantly, PgR is one of the well-defined targets of E₂ regulation. In the absence of E₂, the Pg:PgR stoichiometry may be imbalance. Consequently, the actions of Pg may be limited. In the presence of E₂, the expression of PgR is elevated, allowing more binding of Pg with PgR and subsequent higher PgR-mediated transactivation of targeted genes, leading to a synergistic effect of E₂ and Pg. Recently, Gao et al. have reported that the expression of progesterone receptor is significantly higher than that of estrogen receptor in pulmonary LAM, suggesting a potential role of PgR in LAM pathogenesis [47]. In a preclinical model of LAM, Prizant et al. reported that E₂ or E₂ plus Pg increase the growth of uterine tumors and lung metastasis of uterine tumor cells, although Pg alone did not affect these alterations [24], consistent with our preclinical findings. Despite the lack of effect of Pg in lung metastasis of tumor cells, we observed striking alveolar alterations of immune cell infiltration and alveolar thickening in the lungs of mice treated with Pg. To our knowledge, this is the first report describing a direct effect of progesterone in promoting immune responses and alveolar integrity, suggesting that progesterone may play an important role in LAM pathogenesis and progression.

The impact of estradiol on the growth and metastatic behaviors of TSC2-deficient cells have been reported. Estradiol treatment activated p44/42 MAPK and the proliferation of rat uterine leiomyoma-derived cells [23, 33]. Gu et al. found that estradiol stimulation activates ERK1/2, increases migration and invasion, and promotes epithelial-to-mesenchymal transition of LAM patient-derived cells [35]. Sun et al. reported that estradiol treatment promoted glucose metabolism via enhanced pentose phosphate pathway addiction, increased the glucose uptake in vitro via Akt reactivation, and increased the survival of LAM patient-derived cells in a G6PD-dependent manner [36]. In addition, Li et al. demonstrated that estradiol treatment increased phospholipid-arachidonate breakdown, the expression of COX-2, and the production of prostaglandin metabolites in LAM patient-derived cells [34]. In this study, the effects of E₂ and/or Pg on cell proliferation and survival are subtle, but we repeatedly observe similar trends. One explanation for this subtle hormonal effect on cell proliferation might be caused by decreased ER α and PgR expression in cultures, with more striking effects likely in vivo. In agreement with this, we found that E₂ treatment led to a 2-fold increase of the growth of subcutaneous tumors of ELT3 cells at 8-weeks post cell injection in a xenograft tumor model [23].

Importantly, the migration and invasion of TSC2-deficient cells were more dramatically affected by E₂ and/or Pg treatment. Recent studies showed that E₂ treatment enhanced the migration of human-derived cells [35] and rat-derived ELT3 cells. More importantly, Faslodex treatment blocked the E₂-promoted lung metastasis of ELT3 cells without affecting the growth of xenograft tumors [25]. Collectively, these studies imply a critical

action of E₂ in regulating metastatic behaviors of TSC2-deficient cells more than their proliferation.

We previously showed that estradiol promotes the survival and lung metastasis of Tsc2-deficient ELT3 cells in a MEK1/2-dependent manner [23]. Although the impact of estradiol on the growth and metastatic behaviors of TSC2-deficient cells have been reported, the influence of progesterone in these cellular outcomes has not been extensively investigated in the context of TSC2 deficiency and LAM. Recently, Prizant et al. developed a novel uterine-specific Tsc2 knockout mouse model in which estradiol or estradiol plus progesterone promotes the growth of myometrial tumors and lung metastasis, although progesterone alone had no effect on these phenotypes [24]. In current study, we found that progesterone was sufficient to activate ERK1/2 and Akt signaling pathways, although not sufficient to promote tumor growth or lung metastasis of Tsc2-deficient cells, indicating a potentially key pathogenic mechanism of progesterone action underlying the female hormone-driven progression of LAM.

LAM can lead to respiratory failure and death [3, 15]. Despite many advances in understanding mTOR-dependent and independent pathways and the clinical care of women with LAM, there remains a critical need for improved therapeutic options. The recent MILES trial (Multicenter International LAM Efficacy of Sirolimus Trial) demonstrated that the mTORC1 inhibitor Sirolimus stabilizes lung function in women with LAM; however, lung function decline resumed upon drug discontinuation [4], indicating a curable therapeutic strategy is urgently needed. Our data highlight a mechanism for LAM pathogenesis, for the first time, that progesterone activates MEK1/2 and PI3K/Akt signaling pathways and enhances the migration and invasiveness of TSC2-deficient LAM patient-derived cells. It will be important to further investigate the molecular mechanisms responsible for the action of progesterone in LAM progression and test the efficacy of inhibition of progesterone and progesterone receptor in vitro and in vivo. We anticipate that targeting progesterone signaling may be beneficial in the treatment and/or in the prevention of women with LAM.

Materials and Methods

Cell line and culture

Cell culture media and supplements were from GIBCO (Frederick, MD). Eker rat uterine leiomyoma-derived (ELT3) were developed by Howe et al. [29, 48]. ELT3 cells were transduced with a retroviral plasmid pMSCVneo-hTSC2 or its corresponding empty vector pMSCVneo, and then selected with neomycin for two weeks. Stable clones were characterized for TSC2 expression [49]. The patient-derived cells were developed from a sporadic LAM-associated renal angiomyolipoma. These cells carry bi-allelic mutations of the TSC2 gene that are identical to the mutations found in the patient's pulmonary LAM cells [28]. An E6/E7 immortalized patient-derived cell line was developed [6]. Its corresponding TSC2-rescued control cell line has been described previously [50]. In brief, patient-derived cells were transfected with pcDNA3.1zeo-hTSC2 or its corresponding empty vector control pcDNA3.1zeo. Stable clones expressing TSC2 were selected using zeocin for two weeks as described previously [50]. Cells were cultured in DMEM/F12 supplemented

with 10% fetal bovine serum (FBS), 0.2 μ M hydrocortisone, 0.1 nM triiodothyronine, 0.01 μ U/ml vasopressin, 1.6 μ M FeSO₄, cholesterol, human insulin-transferrin-sodium selenite (ITS), 100 ng/ml epidermal growth factor (EGF), 100 μ g/ml zeomycin, and 1% penicillin-streptomycin-amphotericin B (PSA). One week prior to hormonal treatment, cells were cultured in phenol red-free media supplemented with charcoal-dextran stripped FBS (steroids depleted). All hormonal treatments were performed in phenol red-free and serum-free media.

Antibodies and Chemicals

The following chemicals were used: 17-beta-estradiol, progesterone, ICI 182,780 (Fulvestrant), RU-486 (Mifepristone), and propidium iodide (Sigma-Aldrich). Antibodies included phospho-ERK1/2 (T202/Y204), phospho-Akt (Ser473), phospho-S6 (S235/236), ERK1/2 and PCNA (Cell Signaling Technologies); tuberin (TSC2) (Santa Cruz); CD45 (BD BIOSCIENCES); SPC (Santa Cruz); smooth muscle actin (Biogenex); and β -actin (Sigma-Aldrich).

Immunofluorescent staining

Cells were seeded on glass coverslips and cultured in complete media. Cells were fixed with 4% Paraformaldehyde for 10 min, blocked in 1% BSA/PBS/Tween 20 (0.05%) for 30 min, and incubated with primary antibody for 1 hr and secondary antibodies for 1 hr. Images were captured with an FluoView FV-10i Olympus Laser Point Scanning Confocal Microscope Olympus.

Cell proliferation assay

Cells were seeded at a density of 3×10^4 /mL in 96-well plate for 24 hr, and then treated with control, estradiol (10 nM), progesterone (10 nM). Cell proliferation was measured using crystal violet. Briefly, cells were fixed with formalin for 5 minutes, stained with 0.05% crystal violet (CV) for 30 minutes, washed three times with tap water, and air dried. 100 μ L methanol was added to each well to solubilize the dye thoroughly. Absorbance at 540 nm was read on a plate reader (BioTek Synergy HT).

Transwell migration assay

Cells were pre-incubated with control, estradiol (10 nM), progesterone (10 nM), and estradiol plus progesterone for 24 hr, and then seeded into 24-well Corning transwell. Twenty-four hours later, migrating cells were stained with Crystal violet and quantitated.

Matrigel invasion assay

Cells were pre-incubated with control, estradiol (10 nM), progesterone (10 nM), and estradiol plus progesterone for 24 hr, and then seeded into 6-well BD BioCoat™ Matrigel™ Invasion Chamber (BD Biosciences). Twenty-four hours later, invading cells were stained with Crystal violet and quantitated.

Cellular NADPH quantification

Cells were seeded in 12-well plates, and then stimulated with control, estradiol (10 nM), progesterone (10 nM), and estradiol plus progesterone. 1×10^5 cells were harvested and lysates were extracted with 200 μ L of extraction buffer following the manufacture's instruction. Levels of NADPH were measured using NADP/NADPH Assay kit (Abcam) and normalized to total cellular proteins.

Quantification of reactive oxygen species (ROS)

Cells were seeded in 96-well plates and incubated with 50 μ M DCFH-DA in 1x-DPBS for 45 min at 37°C. Fluorescence was read at 485 nm/525 nm. Levels of cellular ROS were normalized to the total number of cells.

Quantification of intracellular glutathione (GSH)

Cells were seeded in 6-well plates and then treated with control, estradiol (10 nM), progesterone (10 nM), and estradiol plus progesterone for 24 hr. 5×10^5 cells were harvested and whole cell lysates were extracted with 300 μ L extraction buffer by freeze-thaw cycles. Intracellular levels of glutathione (GSH) were quantified (Cayman Glutathione Assay) and normalized to protein amounts.

Measurement of cell survival

Cells were plated in the 96-well plates, treated with control, estradiol (10 nM), progesterone (10 nM), and estradiol plus progesterone for 24 hr, and then exposure to 0.5 μ M H₂O₂ for 30 min. Cells were incubated with 5 μ M propidium iodide in 100 μ L 1x-DPBS for 30 min at 37°C. Fluorescence was read at 530 nm/620 nm. Data was represented as percentage of dead cells relative to the total number of cells.

Immunoblotting

Cells were lysed in M-PER buffer (Pierce) supplemented with protease inhibitors and phosphatase inhibitor cocktails. Cleared cell lysates were obtained by centrifugation at 14,000 $\times$ rpm for 10 min at 4°C and then subjected to immunoblotting.

Animal studies

All animal work was performed in accordance with protocols approved by the Institutional Animal Care and Use Committee-Fox Chase Cancer Center, Philadelphia. For xenograft tumor establishment, one week prior to cell inoculation, mice were implanted with estradiol pellets (90-day release, 1.7 mg/pellet), progesterone pellets (90-day release, 25 mg/pellet), estradiol plus progesterone (1.7 mg + 25 mg/pellet), or placebo pellets (Innovative America). Two million Tsc2-deficient ELT3 cells were inoculated bilaterally into the rear flanks of the mice as described in our previous study[23]. Subcutaneous tumors were developed four weeks post cell inoculation. The volume of xenograft tumor (width $\times$ length $\times$ depth) was measured using a digital caliper. Mice were sacrificed eight-week post cell injection. To identify metastatic lesions, lung sections were stained with smooth muscle actin (SMA), phospho-S6 (Ser235/236), CD45, SPC, and dual staining of PCNA and phospho-S6. The clusters of double positive cells were considered as lung metastases,

resembling the proliferative phenotype of human LAM [38]. Furthermore, lung metastases were scored from 5-micron H&E-stained sections of each lobe by observers blinded to the experimental conditions as described [23]. Sections were deparaffinized and stained with Gill's Hematoxylin and eosin (H&E). The area of alveolar space was scored from 30 random fields per lung section. The ratio of alveolar space to the corresponding lung area was calculated and illustrated in a scatterplot.

Quantitative RT-PCR

Total RNA was extracted using the RNeasy mini kit (Qiagen). cDNA was synthesized from 2 µg of total RNA using a high-capacity cDNA reverse transcription kit (Life Technologies) with random primers, according to the manufacturer's protocol. Gene expression was quantified using SYBR green real-time PCR Master Mixes kit (Life Technologies) in the Applied Biosystems Real-Time PCR System and normalized to tubulin. The primers were used:

ERS1 (ERα): Forward: GCTTACTGACCAACCTGGCAGA.

Reverse: GGATCTCTAGCCAGGCACATTC.

Tubulin forward: GAGGAGATGACTCCTTCAACACC.

Reverse: TGATGAGCTGCTCAGGGTGGAA.

PgR Forward: GTCGCCTTAGAAAGTGCTGTCAG.

Reverse: GCTTGGCTTTCATTTGGAACGCC.

Rat derived cells gene expression was quantified using One-Step qRT-PCR kits (Invitrogen) in the Applied Biosystems Step One Plus Real-Time PCR System and normalized to β-actin. PgR primer mix (Applied Biosystem Rn01448227_m1), EsR1 primer mix (Applied Biosystem Rn01640372_m1) and Rat actin primer mix (Applied Biosystem 4352931).

Statistical analyses

All data are shown as mean ± S.E.M. Measurements at single time points were analyzed by ANOVA and, if they demonstrated significance, were further analyzed by a two-tailed t-test. All statistical tests were conducted using GraphPad Prism 6.0 (GraphPad Software, San Diego, CA, USA). $P < 0.05$ was used to define statistical significance.

Acknowledgments

We are grateful to Dr. C. Walker (Texas A&M Health Science Center) for providing ELT3 cells, Ms. Chunrong Wang for animal experiments, and Mr. Anthony Larro (Fox Chase Cancer Center) for assistance with animal studies, and Dr. E.P. Henske for her critical reading of this manuscript. C.L. is a postdoctoral research fellow funded by The LAM Foundation Fellowship. This study is supported by the National Heart Lung and Blood Institute to (HL98216) to J.J.Y.

References

1. Carsillo T, Astrinidis A, Henske EP. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. *Proc Natl Acad Sci U S A*. 2000; 97(11): 6085–6090. [PubMed: 10823953]

2. Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. *N Engl J Med*. 2006; 355(13):1345–1356. [PubMed: 17005952]
3. Henske EP, McCormack FX. Lymphangioleiomyomatosis - a wolf in sheep's clothing. *J Clin Invest*. 2012; 122(11):3807–3816. [PubMed: 23114603]
4. McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch JP 3rd, Goldberg HJ, Young LR, Kinder BW, Downey GP, Sullivan EJ, Colby TV, McKay RT, Cohen MM, Korbee L, Taveira-DaSilva AM, Lee HS, Krischer JP, Trapnell BC, National Institutes of Health Rare Lung Diseases C, Group MT. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. *N Engl J Med*. 2011; 364(17):1595–1606. [PubMed: 21410393]
5. Karbowiczek M, Astrinidis A, Balsara BR, Testa JR, Lium JH, Colby TV, McCormack FX, Henske EP. Recurrent lymphangiomyomatosis after transplantation: genetic analyses reveal a metastatic mechanism. *Am J Respir Crit Care Med*. 2003; 167(7):976–982. [PubMed: 12411287]
6. Yu J, Astrinidis A, Howard S, Henske EP. Estradiol and tamoxifen stimulate LAM-associated angiomyolipoma cell growth and activate both genomic and nongenomic signaling pathways. *Am J Physiol Lung Cell Mol Physiol*. 2004; 286(4):L694–L700. [PubMed: 12922981]
7. Brentani MM, Carvalho CR, Saldiva PH, Pacheco MM, Oshima CT. Steroid receptors in pulmonary lymphangiomyomatosis. *Chest*. 1984; 85(1):96–99. [PubMed: 6690259]
8. Colley MH, Geppert E, Franklin WA. Immunohistochemical detection of steroid receptors in a case of pulmonary lymphangioleiomyomatosis. *Am J Surg Pathol*. 1989; 13(9):803–807. [PubMed: 2764227]
9. Logginidou H, Ao X, Russo I, Henske EP. Frequent estrogen and progesterone receptor immunoreactivity in renal angiomyolipomas from women with pulmonary lymphangiomyomatosis. *Chest*. 2000; 117(1):25–30. [PubMed: 10631194]
10. Ohori NP, Yousem SA, Sonmez-Alpan E, Colby TV. Estrogen and progesterone receptors in lymphangioleiomyomatosis, epithelioid hemangioendothelioma, and sclerosing hemangioma of the lung. *Am J Clin Pathol*. 1991; 96(4):529–535. [PubMed: 1716416]
11. Tazelaar HD, Kerr D, Yousem SA, Saldana MJ, Langston C, Colby TV. Diffuse pulmonary lymphangiomatosis. *Hum Pathol*. 1993; 24(12):1313–1322. [PubMed: 8276379]
12. Usuki J, Horiba K, Chu SC, Moss J, Ferrans VJ. Immunohistochemical analysis of proteins of the Bcl-2 family in pulmonary lymphangioleiomyomatosis: association of Bcl-2 expression with hormone receptor status. *Arch Pathol Lab Med*. 1998; 122(10):895–902. [PubMed: 9786350]
13. Berger U, Khaghani A, Pomerance A, Yacoub MH, Coombes RC. Pulmonary lymphangioleiomyomatosis and steroid receptors. An immunocytochemical study. *Am J Clin Pathol*. 1990; 93(5):609–614. [PubMed: 2183584]
14. Brunelli A, Catalini G, Fianchini A. Pregnancy exacerbating unsuspected mediastinal lymphangioleiomyomatosis and chylothorax. *Int J Gynaecol Obstet*. 1996; 52(3):289–290. [PubMed: 8775689]
15. Taveira-DaSilva AM, Pacheco-Rodriguez G, Moss J. The natural history of lymphangioleiomyomatosis: markers of severity, rate of progression and prognosis. *Lymphat Res Biol*. 2010; 8(1):9–19. [PubMed: 20235883]
16. Oberstein EM, Fleming LE, Gomez-Marin O, Glassberg MK. Pulmonary lymphangioleiomyomatosis (LAM): examining oral contraceptive pills and the onset of disease. *J Womens Health (Larchmt)*. 2003; 12(1):81–85. [PubMed: 12639372]
17. Yano S. Exacerbation of pulmonary lymphangioleiomyomatosis by exogenous oestrogen used for infertility treatment. *Thorax*. 2002; 57(12):1085–1086. [PubMed: 12454306]
18. Shen A, Iseman MD, Waldron JA, King TE. Exacerbation of pulmonary lymphangioleiomyomatosis by exogenous estrogens. *Chest*. 1987; 91(5):782–785. [PubMed: 3032524]
19. Matsui K, Takeda K, Yu ZX, Valencia J, Travis WD, Moss J, Ferrans VJ. Downregulation of estrogen and progesterone receptors in the abnormal smooth muscle cells in pulmonary lymphangioleiomyomatosis following therapy. An immunohistochemical study. *Am J Respir Crit Care Med*. 2000; 161(3 Pt 1):1002–1009. [PubMed: 10712355]

20. Seyama K, Kira S, Takahashi H, Ohnishi M, Kodama Y, Dambara T, Kobayashi J, Kitamura S, Fukuchi Y. Longitudinal follow-up study of 11 patients with pulmonary lymphangioleiomyomatosis: diverse clinical courses of LAM allow some patients to be treated without anti-hormone therapy. *Respirology*. 2001; 6(4):331–340. [PubMed: 11844125]
21. Taveira-DaSilva AM, Stylianou MP, Hedin CJ, Hathaway O, Moss J. Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone. *Chest*. 2004; 126(6):1867–1874. [PubMed: 15596686]
22. Liu F, Lunsford EP, Tong J, Ashitate Y, Gibbs SL, Yu J, Choi HS, Henske EP, Frangioni JV. Real-time monitoring of tumorigenesis, dissemination, & drug response in a preclinical model of lymphangioleiomyomatosis/tuberous sclerosis complex. *PLoS One*. 2012; 7(6):e38589. [PubMed: 22719903]
23. Yu JJ, Robb VA, Morrison TA, Ariazi EA, Karbowniczek M, Astrinidis A, Wang C, Hernandez-Cuebas L, Seeholzer LF, Nicolas E, Hensley H, Jordan VC, Walker CL, Henske EP. Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells. *Proc Natl Acad Sci U S A*. 2009; 106(8):2635–2640. [PubMed: 19202070]
24. Prizant H, Sen A, Light A, Cho SN, DeMayo FJ, Lydon JP, Hammes SR. Uterine-specific loss of Tsc2 leads to myometrial tumors in both the uterus and lungs. *Mol Endocrinol*. 2013; 27(9):1403–1414. [PubMed: 23820898]
25. Li C, Zhou X, Sun Y, Zhang E, Mancini JD, Parkhitko A, Morrison TA, Silverman EK, Henske EP, Yu JJ. Faslodex inhibits estradiol-induced extracellular matrix dynamics and lung metastasis in a model of lymphangioleiomyomatosis. *Am J Respir Cell Mol Biol*. 2013; 49(1):135–142. [PubMed: 23526212]
26. El-Hashemite N, Walker V, Kwiatkowski DJ. Estrogen enhances whereas tamoxifen retards development of Tsc mouse liver hemangioma: a tumor related to renal angiomyolipoma and pulmonary lymphangioleiomyomatosis. *Cancer Res*. 2005; 65(6):2474–2481. [PubMed: 15781664]
27. Howe SR, Everitt JI, Gottardis MM, Walker C. Estrogen/antiestrogen responsiveness in an in vivo/in vitro model for myometrial tumorigenesis. *Ann N Y Acad Sci*. 1995; 761:373–375. [PubMed: 7625739]
28. Yu JJ, Astrinidis A, Howard S, Henske EP. Estradiol and tamoxifen stimulate LAM-associated angiomyolipoma cell growth and activate both genomic and nongenomic signaling pathways. *Am J Physiol Lung Cell Mol Physiol*. 2004; 286(4):L694–L700. [PubMed: 12922981]
29. Howe SR, Gottardis MM, Everitt JI, Walker C. Estrogen stimulation and tamoxifen inhibition of leiomyoma cell growth in vitro and in vivo. *Endocrinology*. 1995; 136(11):4996–5003. [PubMed: 7588234]
30. Olea-Serrano N, Devleeschouwer N, Leclercq G, Heuson JC. Assay for estrogen and progesterone receptors of breast cancer cell lines in monolayer culture. *Eur J Cancer Clin Oncol*. 1985; 21(8):965–973. [PubMed: 4043179]
31. Kawahara K, Shimazu A. Expression and intracellular localization of progesterone receptors in cultured human gingival fibroblasts. *J Periodontal Res*. 2003; 38(3):242–246. [PubMed: 12753360]
32. Mollerup S, Jorgensen K, Berge G, Haugen A. Expression of estrogen receptors alpha and beta in human lung tissue and cell lines. *Lung Cancer*. 2002; 37(2):153–159. [PubMed: 12140138]
33. Finlay GA, Hunter DS, Walker CL, Paulson KE, Fanburg BL. Regulation of PDGF production and ERK activation by estrogen is associated with TSC2 gene expression. *Am J Physiol Cell Physiol*. 2003; 285(2):C409–C418. [PubMed: 12700139]
34. Li C, Lee PS, Sun Y, Gu X, Zhang E, Guo Y, Wu CL, Auricchio N, Priolo C, Li J, Csibi A, Parkhitko A, Morrison T, Planaguma A, Kazani S, Israel E, Xu KF, Henske EP, Blenis J, Levy BD, Kwiatkowski D, Yu JJ. Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. *J Exp Med*. 2014; 211(1):15–28. [PubMed: 24395886]
35. Gu X, Yu JJ, Ilter D, Blenis N, Henske EP, Blenis J. Integration of mTOR and estrogen-ERK2 signaling in lymphangioleiomyomatosis pathogenesis. *Proc Natl Acad Sci U S A*. 2013; 110(37):14960–14965. [PubMed: 23983265]

36. Sun, Yang; G, X.; Zhang, Erik; Park, Mi-Ae; Pereira, Ana M.; Wang, Shuyan; Morrison, Tasha; Li, Chenggang; Blenis, John; Gerbaudo, Victor H.; Henske, Elizabeth Petri; Yu, Jane J. Estradiol promotes pentose phosphate pathway addiction and cell survival via reactivation of Akt in mTORC1 hyperactive cells. *Cell Death & Disease*. 2014 In print.
37. Acconcia F, Ascenzi P, Bocedi A, Spisni E, Tomasi V, Trentalance A, Visca P, Marino M. Palmitoylation-dependent estrogen receptor alpha membrane localization: regulation by 17beta-estradiol. *Mol Biol Cell*. 2005; 16(1):231–237. [PubMed: 15496458]
38. Goncharova EA, Goncharov DA, Eszterhas A, Hunter DS, Glassberg MK, Yeung RS, Walker CL, Noonan D, Kwiatkowski DJ, Chou MM, Panettieri RA Jr, Krymskaya VP. Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). *J Biol Chem*. 2002; 277(34): 30958–30967. [PubMed: 12045200]
39. McCarty KS Jr, Mossler JA, McLelland R, Sieker HO. Pulmonary lymphangioleiomyomatosis responsive to progesterone. *N Engl J Med*. 1980; 303(25):1461–1465. [PubMed: 7432404]
40. Denoo X, Hermans G, Degives R, Foidart JM. Successful treatment of pulmonary lymphangioleiomyomatosis with progestins: a case report. *Chest*. 1999; 115(1):276–279. [PubMed: 9925099]
41. Johnson SR, Tattersfield AE. Decline in lung function in lymphangioleiomyomatosis: relation to menopause and progesterone treatment. *Am J Respir Crit Care Med*. 1999; 160(2):628–633. [PubMed: 10430739]
42. Urban T, Lazor R, Lacronique J, Murris M, Labrune S, Valeyre D, Cordier JF. Pulmonary lymphangioleiomyomatosis. A study of 69 patients. Groupe d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires (GERM"O"P). *Medicine (Baltimore)*. 1999; 78(5):321–337. [PubMed: 10499073]
43. Schiavina M, Contini P, Fabiani A, Cinelli F, Di Scioscio V, Zompatori M, Campidelli C, Pileri SA. Efficacy of hormonal manipulation in lymphangioleiomyomatosis. A 20-year-experience in 36 patients. *Sarcoidosis Vasc Diffuse Lung Dis*. 2007; 24(1):39–50. [PubMed: 18069418]
44. Harari S, Cassandro R, Chiodini I, Taveira-DaSilva AM, Moss J. Effect of a gonadotrophin-releasing hormone analogue on lung function in lymphangioleiomyomatosis. *Chest*. 2008; 133(2): 448–454. [PubMed: 18071009]
45. Baldi BG, Medeiros Junior P, Pimenta SP, Lopes RI, Kairalla RA, Carvalho CR. Evolution of pulmonary function after treatment with goserelin in patients with lymphangioleiomyomatosis. *J Bras Pneumol*. 2011; 37(3):375–379. [PubMed: 21755194]
46. Johnson SR. Lymphangioleiomyomatosis. *Eur Respir J*. 2006; 27(5):1056–1065. [PubMed: 16707400]
47. Gao L, Yue MM, Davis J, Hyjek E, Schuger L. In pulmonary lymphangioleiomyomatosis expression of progesterone receptor is frequently higher than that of estrogen receptor. *Virchows Arch*. 2014; 464(4):495–503. [PubMed: 24570392]
48. Howe SR, Gottardis MM, Everitt JI, Goldsworthy TL, Wolf DC, Walker C. Rodent model of reproductive tract leiomyomata. Establishment and characterization of tumor-derived cell lines. *Am. J. Pathol*. 1995; 146(6):1568–1579. [PubMed: 7539981]
49. Astrinidis A, Cash TP, Hunter DS, Walker CL, Chernoff J, Henske EP. Tuberin, the tuberous sclerosis complex 2 tumor suppressor gene product, regulates Rho activation, cell adhesion and migration. *Oncogene*. 2002; 21(55):8470–8476. [PubMed: 12466966]
50. Hong F, Larrea MD, Doughty C, Kwiatkowski DJ, Squillace R, Slingerland JM. mTOR-raptor binds and activates SGK1 to regulate p27 phosphorylation. *Mol Cell*. 2008; 30(6):701–711. [PubMed: 18570873]

Figure 1. Progesterone activates Akt and ERK1/2 and enhances the proliferation of TSC2-deficient cells *in vitro*

(A) The relative transcript levels of ERα and PgR in patient-derived cells, rat-derived cells, MCF-7 and BEAS-2B cells. The actual CT values of the ERα and PgR transcript were shown in the tables. (B) Representative immunofluorescent staining images of ERα and PgR in patient-derived cells (621-101), rat-derived cells (ELT3-V3), BEAS-2B and MCF-7 cells. (C) Patient-derived cells were treated with 10 nM E₂, 10 nM progesterone (Pg), 10 nM E₂ + 10 nM Pg, or vehicle control for 0.5, 4, and 24 hr. Immunoblot analysis of phospho-Akt (Ser473), phospho-ERK1/2 (Thr202/Tyr204) and phospho-S6 (S235/236). A densitometry

of phospho-ERK1/2 and ERK1/2 was performed. (D) LAM patient-derived cells were treated with 10 nM E₂, 10 nM progesterone (Pg), 10 nM E₂ + 10 nM Pg, or vehicle control for 24, 48, and 72 hr. Cell proliferation was measured using crystal violet staining assay. (E) Tsc2-deficient rat uterus-derived ELT3 cells were treated with 10 nM E₂, 10 nM progesterone (Pg), 10 nM E₂ + 10 nM Pg, or vehicle control for 24, 48, and 72 hr. Cell proliferation was measured using crystal violet staining assay. (F) Patient-derived cells were in complete media (containing steroids) or in phenol red-free media supplemented with charcoal-dextran stripped FBS (depleting steroids) for 72 hr, and measured cell growth at 24, 48 and 72 hr post cell seeding. Cell proliferation was measured using crystal violet staining assay. * $p < 0.05$, ** $p < 0.01$, Student t test.

Figure 2. Progesterone increases the migration of TSC2-deficient cells

(A) Rat-derived cells and (B) Patient-derived cells were treated with 10 nM E₂, 10 nM progesterone (Pg), 10 nM E₂ + 10 nM Pg, or vehicle control for 24 hr. 20,000 cells were seeded in the upper chamber in the presence of steroids or vehicle. Cell migration was measured using the Boyden chamber transwell assay. Number of cells migrated through the chamber after 24 hr incubation was detected by Crystal Violet staining and quantitated. (B) Patient-derived cells were pre-treated with ICI 182,780 (ICI, 10 μM) or RU-486 (RU, 20 μM) for 12 hr, and then stimulated with 10 nM E₂, 10 nM Pg, 10 nM E₂ + 10 nM Pg, or

vehicle control for 24 hr. Cell migration was measured using the Boyden chamber transwell assay. Number of cells migrated through the chamber was detected by Crystal Violet staining and quantitated. Data are mean $\pm$ SEM, n = 3 in triplicate. * $p < 0.05$, ** $p < 0.01$, Student *t* test.

Figure 3. Progesterone enhances the invasiveness of TSC2-deficient cells
 (A) Rat-derived cells and (B) Patient-derived cells were treated with 10 nM E₂, 10 nM progesterone (Pg), 10 nM E₂ + 10 nM Pg, or vehicle control for 24 hr. 2×10^6 cells were seeded in a Matrigel-coated upper chamber in the presence of steroids or vehicle. Cell invasion was assessed using Matrigel invasion assay. (B) Patient-derived cells were pre-treated with ICI 182,780 (ICI, 10 μ M) or RU-486 (RU, 20 μ M) for 12 hr, and then stimulated with 10 nM E₂, 10 nM Pg, 10 nM E₂ + 10 nM Pg, or vehicle control for 24 hr. Cell invasion was assessed using Matrigel invasion assay. Number of cells invaded through

the Matrigel was detected by Crystal Violet staining and quantitated. Data are mean $\pm$ SEM, n = 3 in triplicate. * p < 0.05, ** p < 0.01, Student *t* test.

Figure 4. Progestone and estradiol synergistically decrease ROS and increase GSH in TSC2-deficient cells

(A) Cellular levels of ROS were measured using DCFH-DA in patient-derived or rat-derived cells grown in serum-free conditions. (B) Rat-derived cells and (C) LAM patient-derived cells were treated with 10 nM E₂, 10 nM Pg, 10 nM E₂ + 10 nM Pg, or vehicle control for 24 hr. Cells were incubated with hydrogen peroxide (0.5 μ M) for 30 min prior to the measurement. Cellular levels of ROS were quantified using DCFH-DA. Data was normalized to total cell number. Results are representative of eight independent samples per group from three experiments. (D) Cellular levels of NADPH were measured in LAM

patient-derived cells treated with 10 nM E₂, 10 nM Pg, 10 nM E₂ +10 nM Pg, or vehicle control for 24 hr. Data was normalized to total protein level. (E) Cellular levels of GSH were measured in patient-derived cells treated with 10 nM E₂, 10 nM Pg, 10 nM E₂ +10 nM Pg, or vehicle control for 24 hr. Data was normalized to total protein levels. Results are representative of three sets of independent samples per group from three experiments. * $p < 0.05$, ** $p < 0.01$, Student t test.

Figure 5. Progesterone and estradiol synergistically attenuate the death of TSC2-deficient cells under oxidative stress

(A) Patient-derived TSC2-deficient cells or (B) Rat-derived ELT3 cells were treated with 10 nM E_2 , 10 nM progesterone (Pg), 10 nM E_2 + 10 nM Pg, or vehicle control for 24 hr, and then incubated with 0.5 μ M H_2O_2 for 30 min. Cell morphology was recorded using phase-contrast microscopy. (C) Rat-derived cells and (D) patient-derived cells were treated with 10 nM E_2 , 10 nM Pg, 10 nM E_2 + 10 nM Pg, or vehicle control for 24 hr, and then incubated with 0.5 μ M H_2O_2 for 30 min. Cell death was measured using the propidium iodide (PI) exclusion assay. Proportion of dead cells was normalized to the total number of variable

cells. Results are representative of eight independent samples per group from three experiments. (E) Patient-derived TSC2-deficient cells were pre-treated with ICI 182,780 (ICI, 10 μ M) or RU-486 (RU, 20 μ M) for 12 hr, stimulated with 10 nM E₂, 10 nM Pg, 10 nM E₂ + 10 nM Pg, or vehicle control for 24 hr, and then incubated with 0.5 μ M H₂O₂ for 0.5 hr. Cell death was measured using the propidium iodide (PI) exclusion assay. Proportion of dead cells was normalized to the total number of viable cells. Results are representative of eight independent samples per group from three experiments.* $p < 0.05$, ** $p < 0.01$, Student t test.

Figure 6. Progesterone and estradiol synergistically promote lung metastasis of Tsc2-deficient cells in a preclinical model of LAM

ELT3 cells were subcutaneously injected into female ovariectomized mice implanted with slow-releasing pellets of E₂, progesterone, E₂+progesterone, or placebo. (A) The tumor volume was calculated at eight-week post cell inoculation. (B) The number of lung metastases in female mice was scored: placebo (P) (n = 10), E₂ (n = 8), progesterone (Pg) (n = 4), and E₂ plus progesterone (E₂+Pg) (n = 4). *p<0.05, ** p < 0.01, Student *t* test. (C) Lung sections from female mice were stained with H&E. Arrowheads point to metastatic

lesions in mouse lungs. (D) Immunohistochemical staining of smooth muscle actin (SMA) and phospho-S6 (Ser235/235) in mouse lung sections. (E) Immunofluorescent double staining of phospho-S6 and PCNA in mouse lung sections.

Figure 7. Progesterone induces alveolar wall thickening in a preclinical model of LAM
 Rat-derived ELT3 cells were subcutaneously injected into female ovariectomized mice implanted with slow-releasing pellets of E_2 , Pg, $E_2 + Pg$, or placebo. (A) Lung sections from female mice 29 were stained with H&E. (B) Quantification of alveolar air space in mouse lungs from all treatment groups. The area of alveolar space was scored from 30 random fields per lung section. The ratio of alveolar space to the corresponding lung area was calculated and illustrated in a scatterplot. (C) Immunohistochemical staining of CD45 in

mouse lung sections. (D) Immunofluorescent staining of SPC in mouse lung sections.

* $p < 0.05$, ** $p < 0.01$, Student t test.